Mometasone furoate nasal spray plus oxymetazoline nasal spray: Short-term efficacy and safety in seasonal allergic rhinitis

American Journal of Rhinology and Allergy

Volumn 27, Issue 2, 2013, Pages 102-108

  Meltzer, Eli O ^a   Bernstein, David I ^b   Prenner, Bruce M ^c   Berger, William E ^d   Shekar, Tulin ^e   Teper, Ariel A ^e  

^a ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c Allergy Associates Medical Group Inc   (United States)

^d Allergy and Asthma   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOMETASONE FUROATE; NOSE SPRAY; OXYMETAZOLINE; PLACEBO;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; ESOPHAGUS HEMORRHAGE; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NERVOUSNESS; NOSE DISEASE; NOSE OBSTRUCTION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; SIDE EFFECT; SINUS HEADACHE; THORAX PAIN; THROAT IRRITATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; ANTI-ALLERGIC AGENTS; CHILD; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HISTAMINE H1 ANTAGONISTS; HUMANS; MIDDLE AGED; NASAL OBSTRUCTION; NASAL SPRAYS; OXYMETAZOLINE; RHINITIS, ALLERGIC, SEASONAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 84876028466     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2013.27.3864     Document Type: Article

References (22)

1. Blaiss MS, Meltzer EO, Derebery MJ, et al. Patient and healthcareprovider perspectives on the burden of allergic rhinitis. Allergy Asthma Proc 28(suppl 1):S4-S10, 2007.
2. Meltzer EO, Shekar T, and Teper AA. Mometasone furoate nasal spray for moderate-To-severe nasal congestion in subjects with seasonal allergic rhinitis. Allergy Asthma Proc 32:159-167, 2011.
3. Clement P, and Gates D. Symptom suppression in subjects with perennial allergic rhinitis treated with mometasone furoate nasal spray. Int Arch Allergy Immunol 157:387-390, 2012.
4. Yamada T, Yamamoto H, Kubo S, et al. Efficacy of mometasone furoate nasal spray for nasal symptoms, quality of life, rhinitisdisturbed sleep, and nasal nitric oxide in patients with perennial allergic rhinitis. Allergy Asthma Proc 33:e9-e16, 2012.
5. Salapatek AM, Patel P, Gopalan G, and Varghese ST. Mometasone furoate nasal spray provides early, continuing relief of nasal congestion and improves nasal patency in allergic patients. Am J Rhinol Allergy 24:433-438, 2010.
6. Eskiizmir G, Hirçin Z, Ozyurt B, and Unlü H. A comparative analysis of the decongestive effect of oxymetazoline and xylometazoline in healthy subjects. Eur J Clin Pharmacol 67:19-23, 2011.
7. Naclerio RM, Hadley JA, Stoloff S, et al. Patient and physician perspectives on the attributes of nasal allergy medications. Allergy Asthma Proc 28(suppl 1):S11-S17, 2007.
8. Passali D, Salerni L, Passali GC, et al. Nasal decongestants in the treatment of chronic nasal obstruction: efficacy and safety of use. Expert Opin Drug Saf 5:783-790, 2006.
9. Wallace DV, Dykewicz MS, Bernstein DI, et al.; Joint Task Force on Practice; American Academy of Allergy; Asthma & Immunology; American College of Allergy; Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122(suppl 2):S1-S84, 2008.
10. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 126:466-476, 2010.
11. Bousquet J, Khaltaev N, Cruz AA, et al.; World Health Organization; GA2LEN; AllerGen. Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 63(suppl 86):8-160, 2008.
12. Vaidyanathan S, Williamson P, Clearie K, et al. Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion. Am J Respir Crit Care Med 182:19-24, 2010.
13. Baroody FM, Brown D, Gavanescu L, et al. Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 127:927-934, 2011.
14. Juniper EF, Thompson AK, Ferrie PJ, and Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol 104:364-369, 1999.
15. Barnes ML, Vaidyanathan S, Williamson PA, and Lipworth BJ. The minimal clinically important difference in allergic rhinitis. Clin Exp Allergy 40:242-250, 2010.
16. Juniper EF, Guyatt GH, Griffith LE, and Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 98:843-845, 1996.
17. Merck & Co., Inc. Nasonex package insert. Whitehouse Station, NJ; April 2012.
18. Watanabe H, Foo TH, Djazaeri B, et al. Oxymetazoline nasal spray three times daily for four weeks in normal subjects is not associated with rebound congestion or tachyphylaxis. Rhinology 41:167-174, 2003.
19. Yoo JK, Seikaly H, and Calhoun KH. Extended use of topical nasal decongestants. Laryngoscope 107:40-43, 1997.
20. Ramey JT, Bailen E, and Lockey RF. Rhinitis medicamentosa. J Investig Allergol Clin Immunol 16:148-155, 2006.
21. Graf P. Rhinitis medicamentosa: Aspects of pathophysiology and treatment. Allergy 52(suppl):28-34, 1997.
22. Tas A, Yagiz R, Yalcin O, et al. Use of mometasone furoate aqueous nasal spray in the treatment of rhinitis medicamentosa: An experimental study. Otolaryngol Head Neck Surg 132:608-612, 2005.